The effects of physostigmine infusion on patients with panic disorder.
M H Rapaport, S C Risch, J C Gillin, S Golshan, D Janowsky
Index: Biol. Psychiatry 29(7) , 658-64, (1991)
Full Text: HTML
Abstract
Nine patients who met both DSM-III and RDC criteria for panic disorder and nine age-matched normal controls received infusions of physostigmine. The patients and normal controls did not differ in either their self-reported or the observer-reported ratings of anxiety, mood, or activation. The two subject groups also did not differ in blood pressure, pulse, or cortisol responses to physostigmine. Physostigmine did not provoke panic attacks in either the control or patients groups.
Related Compounds
Related Articles:
2012-12-01
[Behav. Brain Res. 235(2) , 231-43, (2012)]
Development and optimization of a sublingual tablet formulation for physostigmine salicylate.
2009-09-01
[Acta. Pharm. 59(3) , 301-12, (2009)]
Liquid chromatographic analysis of physostigmine salicylate and its degradation products.
1999-01-01
[J. Pharm. Biomed. Anal. 18(6) , 939-45, (1999)]
1988-04-26
[Brain Res. 447(1) , 122-32, (1988)]
Toxicity study of continuous administration of physostigmine salicylate.
1988-11-01
[Pharmacol. Biochem. Behav. 31(3) , 627-31, (1988)]